Last reviewed · How we verify
Nivolumab plus Ipilimumab (nivolumab-plus-ipilimumab)
Nivolumab and ipilimumab work together to enhance immune response against cancer cells by targeting PD-1 and CTLA-4 receptors, respectively.
At a glance
| Generic name | nivolumab-plus-ipilimumab |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Mechanism of action
Nivolumab blocks the PD-1 receptor, preventing cancer cells from evading the immune system, while ipilimumab inhibits CTLA-4, further boosting T-cell activity against tumors.
Approved indications
Common side effects
- Fatigue
- Diarrhoea
- Nausea
- Pruritus
- Decreased appetite
- Rash
- Anaemia
- Constipation
- Vomiting
- Pyrexia
- Cough
- Hypothyroidism
Key clinical trials
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
- A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nivolumab plus Ipilimumab CI brief — competitive landscape report
- Nivolumab plus Ipilimumab updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI